keyword
MENU ▼
Read by QxMD icon Read
search

HIV statin cardiovascular

keyword
https://www.readbyqxmd.com/read/28839514/cholesterol-screening-and-statin-prescription-is-low-among-hiv-infected-patients-on-protease-inhibitor-regimens-in-botswana
#1
M Mosepele, V Letsatsi, L Mokgatlhe, F P Hudson, R Gross
BACKGROUND: Little is known about the use of statin for cardiovascular disease (CVD) risk reduction among HIV-infected patients on protease inhibitors (PI`s) in sub-Saharan Africa (SSA). OBJECTIVE: Cholesterol screening and statin use were retrospectively assessed among HIV-infected participants on PI`s between 2008 and 2012 at a large urban HIV clinic in Botswana. METHODS: Proportion of participants screened per year was calculated and statin indication was assessed using atherosclerosis CVD (ASCVD) and Framingham risk (FRS) scores as of the year 2012 guidelines...
2017: Open AIDS Journal
https://www.readbyqxmd.com/read/28832368/are-we-successfully-managing-cardiovascular-disease-in-people-living-with-hiv
#2
Camilla I Hatleberg, Jens D Lundgren, Lene Ryom
PURPOSE OF REVIEW: The aim of this study was to discuss the most recent research in the management of cardiovascular disease (CVD) in people living with HIV (PLWHIV) with a focus on screening, primary and secondary prevention. RECENT FINDINGS: The cause of CVD in PLWHIV is complex and multifactorial and creates a demand for a multifaceted approach to screening and prevention. Current screening and management of CVD risk factors in PLWHIV is suboptimal, reasons for this are not clear and the data are still scarce both in the primary and secondary preventive setting...
August 21, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28793863/cardiovascular-risk-and-dyslipidemia-among-persons-living-with-hiv-a-review
#3
REVIEW
Paolo Maggi, Antonio Di Biagio, Stefano Rusconi, Stefania Cicalini, Maurizio D'Abbraccio, Gabriella d'Ettorre, Canio Martinelli, Giuseppe Nunnari, Laura Sighinolfi, Vincenzo Spagnuolo, Nicola Squillace
BACKGROUND: Aim of this review is to focus the attention on people living with HIV infection at risk of developing a cardiovascular event. What is or what would be the most suitable antiretroviral therapy? Which statin or fibrate to reduce the risk? How to influence behavior and lifestyles? DISCUSSION: Prevention of cardiovascular disease (CVD) risk remains the first and essential step in a medical intervention on these patients. The lifestyle modification, including smoking cessation, increased physical activity, weight reduction, and the education on healthy dietary practices are the main instruments...
August 9, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28724498/patients-with-hiv-and-coronary-disease-are-we-meeting-national-guidelines
#4
Sam Emmanuel, James Nadel, Damien Fagan, Sirinya Teeraananchai, Matthew Law, Cameron J Holloway
Cardiovascular disease (CVD) has a higher incidence in patients with HIV infection. This study sought to determine whether HIV-infected patients with established CVD were being managed according to national guidelines. Data were collected from Australian general practitioners for 77 HIV-infected patients with a median age of 59 (range 54-64). There was good adherence to guidelines with regards to anti-platelet (84%; n=65; 95% confidence interval (CI) 74-92%) and statin therapy (97%; n=75; 95% CI 91-100%), despite a failure to meet cholesterol targets, with only 31% (n=24; 95% CI 21-42%) of the cohort meeting low-density lipoprotein target values...
July 20, 2017: Sexual Health
https://www.readbyqxmd.com/read/28713869/association-of-anisocytosis-with-markers-of-immune-activation-and-exhaustion-in-treated-hiv
#5
Sadeer G Al-Kindi, David A Zidar, Grace A McComsey, Chris T Longenecker
BACKGROUND: Treated HIV infection is associated with heightened inflammation which can contribute to increased risk of cardiovascular disease (CVD). We have previously shown that anisocytosis, as measured by red cell distribution width (RDW), is independently associated with prevalent CVD in people living with HIV (PLHIV). In this study, we sought to identify immune correlates of RDW in PLHIV receiving antiretroviral therapy. METHODS: We performed a cross-sectional and longitudinal analysis of 147 virally-suppressed PLHIV, who had LDL < 130 mg/dL and evidence of heightened inflammation, in a randomized trial of statin therapy...
2017: Pathogens & Immunity
https://www.readbyqxmd.com/read/28674084/utility-of-2013-american-college-of-cardiology-american-heart-association-cholesterol-guidelines-in-hiv-infected-adults-with-carotid-atherosclerosis
#6
Binh An P Phan, Bernard Weigel, Yifei Ma, Rebecca Scherzer, Danny Li, Sophia Hur, S C Kalapus, Steven Deeks, Priscilla Hsue
BACKGROUND: Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is unknown whether guidelines can identify HIV-infected adults who may benefit from statins. We compared the 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III recommendations in HIV-infected adults and evaluated associations with carotid artery intima-media thickness and plaque. METHODS AND RESULTS: Carotid artery intima-media thickness was measured at baseline and 3 years later in 352 HIV-infected adults without clinical atherosclerotic CVD and not on statins...
July 2017: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28664622/subclinical-atherosclerosis-in-low-framingham-risk-hiv-patients
#7
Rafael León, Sergio Reus, Nicolás López, Irene Portilla, José Sánchez-Payá, Livia Giner, Vicente Boix, Esperanza Merino, Diego Torrús, Óscar Moreno, Joaquín Portilla
BACKGROUND: Pathogenesis of atherosclerosis is complex and differences between HIV-infected patients and general population cannot be completely explained by the higher prevalence of traditional cardiovascular risk factors. We aimed to analyse the association between inflammation and subclinical atherosclerosis in HIV patients with low Framingham risk score. MATERIALS AND METHODS: Case-control study. SETTING: outpatient Infectious Diseases clinic in a university hospital...
June 29, 2017: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28536104/development-and-validation-of-qrisk3-risk-prediction-algorithms-to-estimate-future-risk-of-cardiovascular-disease-prospective-cohort-study
#8
Julia Hippisley-Cox, Carol Coupland, Peter Brindle
Objectives To develop and validate updated QRISK3 prediction algorithms to estimate the 10 year risk of cardiovascular disease in women and men accounting for potential new risk factors.Design Prospective open cohort study.Setting General practices in England providing data for the QResearch database.Participants 1309 QResearch general practices in England: 981 practices were used to develop the scores and a separate set of 328 practices were used to validate the scores. 7.89 million patients aged 25-84 years were in the derivation cohort and 2...
May 23, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#9
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#10
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
July 2017: Lancet HIV
https://www.readbyqxmd.com/read/28364370/recommendations-for-managing-drug-drug-interactions-with-statins-and-hiv-medications
#11
REVIEW
Barbara S Wiggins, Donald G Lamprecht, Robert L Page, Joseph J Saseen
The discovery of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) has enabled individuals to live longer. As a result, HIV is now often considered a chronic condition. However, as a result of the increase in longevity or the HIV treatment modalities themselves, individuals with HIV are at high risk for the development of atherosclerotic cardiovascular disease. Therefore, these patients should be optimized with pharmacologic therapy to lower their cardiovascular risk through the addition of statin therapy to their regimen...
April 1, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/28265887/coronary-artery-disease-in-hiv-infected-patients-downside-of-living-longer
#12
REVIEW
John Charles A Lacson, Revery P Barnes, Hossein Bahrami
PURPOSE OF REVIEW: Introduction of combination antiretroviral therapy (ART) has increased the life expectancy of patients with HIV infection, allowing them to live longer with this chronic medical condition and consequently experiencing conditions such as cardiovascular diseases (CVDs). Several studies have investigated the increased risk of CVD in people living with HIV (PLWH). However, less is known about the exact mechanisms involved in this increased risk. Also, specific guidelines for management of CVD in PLWH have not been developed yet...
April 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/28249009/current-use-of-statins-reduces-risk-of-hiv-rebound-on-suppressive-haart
#13
MULTICENTER STUDY
Henning Drechsler, Colby Ayers, James Cutrell, Naim Maalouf, Pablo Tebas, Roger Bedimo
BACKGROUND: Despite compelling evidence for activity against HIV-1 in vitro, a virologic effect of statins has not been shown in clinical studies. Given their short plasma half-lives, such an effect may be transient and only apparent during ongoing exposure. METHODS: We studied all HIV infected US-Veterans who started HAART 1995-2011, had a documented HIV viral load (VL) >1000 copies/mL, reached an undetectable VL on HAART, and had ≥1 follow-up VL within 13 months...
2017: PloS One
https://www.readbyqxmd.com/read/28208120/cardiovascular-complications-of-hiv-infection
#14
REVIEW
Marshall J Glesby
HIV-infected individuals are at increased risk for cardiovascular events. Widely used cardiovascular disease (CVD) risk calculators to determine indications for statin treatment are not well validated for use in the HIV-infecte population. Some experts advocate including HIV infection as an independent risk factor for CVD. The effects of antiretroviral therapy on lipid profiles and the potentially increased risk for cardiovascular events must be taken into account when selecting treatment for HIV-infected individuals...
December 2017: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/28182617/statins-in-hiv-infected-patients-potential-beneficial-effects-and-clinical-use
#15
Enrique Bernal, Irene Marín, Mar Masiá, Félix Gutiérrez
Patients living with HIV have an increased risk of cardiovascular disease that is considered to be the result of an interaction between traditional cardiovascular risk factors, particularly smoking and dyslipidemia, and persistent chronic inflammation and immune activation associated with HIV infection, along with side effects of antiretroviral therapy. In the general population, the administration of statins has been associated with a reduction in cardiovascular disease-associated mortality, and these drugs are among the most common class of medication prescribed in high-income countries...
April 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28121706/greater-remnant-lipoprotein-cholesterol-reduction-with-pitavastatin-compared-with-pravastatin-in-hiv-infected-patients
#16
Parag H Joshi, P Elliott Miller, Seth S Martin, Steven R Jones, Joseph M Massaro, Ralph B D'Agostino, Krishnaji R Kulkarni, Craig Sponseller, Peter P Toth
OBJECTIVE: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in those with HIV. An emerging CVD risk factor is triglyceride-rich remnant lipoprotein cholesterol (RLP-C: the sum of intermediate-density lipoprotein and very low-density lipoprotein cholesterol). The effects of statin therapy on lipoprotein subfractions, including RLP-C, in HIV dyslipidemia are unknown. METHODS: This is a post hoc analysis of the randomized INTREPID trial (NCT 01301066) comparing pitavastatin 4 mg daily vs...
April 24, 2017: AIDS
https://www.readbyqxmd.com/read/28072892/use-of-statins-and-aspirin-to-prevent-cardiovascular-disease-among-hiv-positive-patients-a-survey-among-italian-hiv-physicians
#17
Paolo Maggi, Giuseppe Vittorio De Socio, Stefania Cicalini, Maurizio D'Abbraccio, Gabriella Dettorre, Antonio Di Biagio, Canio Martinelli, Giuseppe Nunnari, Stefano Rusconi, Laura Sighinolfi, Vincenzo Spagnuolo, Nicola Squillace
We conducted a survey among Italian HIV specialists to study the utilization of statins and aspirin, administering a questionnaire aimed at investigating their use, the use of guidelines and scores, and the management of interactions. The answers were uniform in the different geographic areas. The majority directly prescribe statins and 43% of them prescribe aspirin. The majority follows guidelines and utilize scores to calculate the CV risk. Our survey demonstrates the commitment and autonomy in prescribing statins and aspirin of Italian physicians...
April 2017: New Microbiologica
https://www.readbyqxmd.com/read/28062146/intensive-statin-regimens-for-reducing-risk-of-cardiovascular-diseases-among-human-immunodeficiency-virus-infected-population-a-nation-wide-longitudinal-cohort-study-2000-2011
#18
Huang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, Chen-Yi Yang, Nai-Ying Ko
OBJECTIVE: This study evaluated the risk of cardiovascular diseases (CVD) in a statin-treated HIV-infected population and the effects of intensive statin regimens (i.e., high-dose or potency) on CVD risks. METHODS: 945 HIV-infected patients newly on statin treatment (144, 15.7% with CVD history) were identified from Taiwan's national HIV cohort. Using the median of the first year cumulative statin dosage as a cut-off point, patients were classified into either a high-dose or low-dose group...
March 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28045766/baseline-vitamin-d-deficiency-decreases-the-effectiveness-of-statins-in-hiv-infected-adults-on-antiretroviral-therapy
#19
RANDOMIZED CONTROLLED TRIAL
Corrilynn O Hileman, Vin Tangpricha, Abdus Sattar, Grace A McComsey
OBJECTIVE: Vitamin D deficiency is common in HIV. Statins may increase vitamin D, and it is unknown whether vitamin D modifies the effect of statins on cardiovascular disease. DESIGN: SATURN-HIV was a 96-week, randomized, placebo-controlled trial designed to evaluate the effect of rosuvastatin on immune activation and subclinical vascular disease in HIV-infected adults on antiretroviral therapy. This analysis focuses on the prespecified secondary endpoint 25-hydroxyvitamin D [25(OH)D] concentrations...
April 15, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28011249/lack-of-effects-of-statins-on-high-density-lipoprotein-subfractions-in-hiv-1-infected-patients-receiving-protease-inhibitors
#20
Randa Bittar, Élisabeth Aslangul, Philippe Giral, Lambert Assoumou, Marc-Antoine Valantin, Olga Kalmykova, Marie-Christine Federspiel, Corinne Cherfils, Dominique Costagliola, Dominique Bonnefont-Rousselot
BACKGROUND: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk. METHODS: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls...
February 2017: Comptes Rendus Biologies
keyword
keyword
14739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"